Who are Lactobacillus casei's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): L. reuteri Prodentis® lozenges, Mixture of three Bifidobacteria, Trimo-San vaginal gel, Probiotic capsules, Gynomunal® gel, Clotrimazole vaginal tablets+ Lactobacillus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-casei.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lactobacillus casei — Competitive Intelligence Brief

Lactobacillus casei (Lactobacillus casei) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology / Immunology.

marketed Probiotic Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Lactobacillus casei (Lactobacillus casei) — Hospital Cristo Re. Lactobacillus casei is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lactobacillus casei TARGET	Lactobacillus casei	Hospital Cristo Re	marketed	Probiotic
L. reuteri Prodentis® lozenges	L. reuteri Prodentis® lozenges	University of Zagreb	marketed	Probiotic
Mixture of three Bifidobacteria	Mixture of three Bifidobacteria	Federico II University	marketed	Probiotic
Trimo-San vaginal gel	Trimo-San vaginal gel	The University of Texas Health Science Center, Houston	marketed	Vaginal pH regulator / Probiotic adjunct
Probiotic capsules	Probiotic capsules	Sahlgrenska University Hospital	marketed	Probiotic
Gynomunal® gel	Gynomunal® gel	Derming SRL	marketed	Vaginal probiotic/microbiota restorer
Clotrimazole vaginal tablets+ Lactobacillus	Clotrimazole vaginal tablets+ Lactobacillus	Peking University Shenzhen Hospital	marketed	Antifungal + probiotic combination	Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus casei — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-casei. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab